Replies to post #63991 on Biotech Values

[DewDiligence]

Recent Biotech Buyouts at a Large Premium

[Added SGXP.]

 
 Acquired         Premium    Deal         iHub  
 Company  Buyer   to Market  Value  Date  Reference  
 KOSN     BMY       233%     $190M  5/08  #msg-29647147 
 COLY     PFE       167%     $165M 11/07  #msg-24600805 
 IOMI     Intercell 147%     $190M  5/08  #msg-29232165  
 BTRX     Stiefel   136%     $150M  6/08  #msg-30201906 
 SGXP     LLY       119%     $64M   7/08  #msg-30547648 
 ENCY     PFE       118%     $350M  2/08  #msg-26978155 
 TRCA     Ipsen     104%     $660M  6/08  #msg-29795183  
 SIRT     GSK        85%     $620M  4/08  #msg-28705020  
 Jerini   Shire     *71%     $520M  7/08  #msg-30452872 
 MLNM     Takeda     53%     $8.8B  4/08  #msg-28365383 
 APPX     Fresenius †29%     $940M  7/08  #msg-30498388 
  
 *199% premium to volume-weighted 
 price during preceding 3 months. 
  
 †Premium reaches 63% if earn-out met.

[daved]

Actually APPX is a generic injectable company and has been same since the spinoff.

As it was bought on the basis of proven profits it dilutes the message of the great recent buyouts.

Dave